Results 61 to 70 of about 109,215 (254)

Thrombocytopenia in the ICU: disseminated intravascular coagulation and thrombotic microangiopathies—what intensivists need to know

Critical Care, 2018
Thrombocytopenia affects 25–55% of intensive care unit (ICU) patients [1]. The reasons for thrombocytopenia in the ICU are numerous, including, among others, sepsis, drugs, and the use of extracorporeal devices (Fig. 1) [1].
J. Vincent, P. Castro, B. Hunt, A. Jörres, M. Praga, J. Rojas-Suarez, Eizo Watanabe   +6 more
semanticscholar   +1 more source

Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in a renal transplant recipient case report

Brazilian Journal of Nephrology, 2020
Thrombotic microangiopathies are disorders characterized by nonimmune microangiopathic hemolytic anemia, thrombocytopenia, and multi-systemic failure.
John Fredy Nieto-Rios, Monica Zuluaga-Quintero, Julio Cesar Valencia-Maturana, Diana Carolina Bello-Marquez, Arbey Aristizabal-Alzate, Gustavo Adolfo Zuluaga-Valencia, Lina Maria Serna-Higuita, Luis Fernando Arias   +7 more
doaj   +2 more sources

Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure [PDF]

, 2016
BACKGROUND AND AIMS: Circulating levels of von Willebrand factor (vWF) predict mortality in patients with cirrhosis. We hypothesized that systemic inflammation in acute-on-chronic liver failure (ACLF) will stimulate endothelium, increase vWF levels, and ...
Amirtharaj, GJ, Balasubramanian, KA, Eapen, CE, Elias, E, Goel, A, Mackie, I, Prasanna, KS, Ramachandran, A, Sajith, KG, Zachariah, U   +9 more
core   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source

Porcine kidney xenotransplantation: From primate models to clinical reality

Animal Models and Experimental Medicine, EarlyView.
In the face of a critical shortage of human donor kidneys for end‐stage renal disease patients, porcine kidney xenotransplantation has emerged as a viable solution. This field has navigated major hurdles, including immune rejection, physiological incompatibilities, potential biomechanical differences and the risk of cross‐species infection. To overcome
Zihang Guo, Ling Zhang, Shoulong Deng, Chuan Qin   +3 more
wiley   +1 more source

Extrarenal manifestations of complement mediated thrombotic microangiopathies

Frontiers in Pediatrics, 2014
Thrombotic microangiopathies (TMA) are rare but severe disorders, characterized by endothelial cell activation and thrombus formation leading to hemolytic anemia, thrombocytopenia and organ failure.
Johannes eHofer, Alejandra eRosales, Caroline eFischer, Thomas eGiner   +3 more
doaj   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source

Eculizumab in secondary atypical haemolytic uraemic syndrome [PDF]

, 2017
Background. Complement dysregulation occurs in thrombotic microangiopathies (TMAs) other than primary atypical haemolytic uraemic syndrome (aHUS). A few of these patients have been reported previously to be successfully treated with eculizumab.
Aljama, Pedro, Arjona, Emi, Blasco, Miquel, Borrego, Josefa, Cao, Mercedes, Cavero, Teresa, Espinosa, Mario, Fuentes, Carolina, García, Alba, Gavela, Eva, González-Parra, Emilio, Gracia-Iguacel, Carolina, Huerta, Ana, Jarque, Ana, López, Antía, Macía, Manuel, Mendizabal, Santiago, Morales, Enrique, Portolés, José, Praga, Manuel, Quintana, Luis F., Rabasco, Cristina, Rodríguez de Córdoba, Santiago, Rojas-Rivera, Jorge, Romera, Ana María, Román, Elena, Sevillano, Ángel, Ávila, Ana   +27 more
core   +2 more sources

Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib

Case Reports in Hematology, 2018
Drug-induced thrombotic microangiopathies (DTMAs) are increasingly being recognized as an important category of thrombotic microangiopathies (TMAs). Cancer therapeutic agents including proteasome inhibitors (PIs) are among the most common medications ...
Suheil Albert Atallah-Yunes, Myat Han Soe   +1 more
doaj   +1 more source

Diclofenac-induced thrombotic thrombocytopenic purpura with concomitant complement dysregulation: a case report and review of the literature

Journal of Medical Case Reports, 2019
Background Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are two forms of thrombotic microangiopathies. They are characterized by severe thrombocytopenia, microangiopathic hemolysis, and thrombosis, leading to a systemic inflammatory ...
Jose Perez Lara, Yaneidy Santana, Maneesh Gaddam, Asghar Ali, Sandeep Malik, Misbahuddin Khaja   +5 more
doaj   +1 more source